INDEMNIFICATION AGREEMENTIndemnification Agreement • November 9th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [ ], 2020 between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
MARAVAI LIFESCIENCES HOLDINGS, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 25th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of November 24, 2020 among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), each of the investors listed on the signature pages hereto under the caption “Sponsor Investors” (collectively, the “Sponsor Investors”), and each Person listed on the signature pages under the caption “Other Investors” or who executes a Joinder as an “Other Investor” (collectively, the “Other Investors”). Except as otherwise specified herein, all capitalized terms used in this Agreement are defined in Exhibit A attached hereto.
CREDIT AGREEMENT DATED AS OF OCTOBER 19, 2020 AMONG MARAVAI INTERMEDIATE HOLDINGS, LLC, AS PARENT BORROWER, CYGNUS TECHNOLOGIES, LLC, TRILINK BIOTECHNOLOGIES, LLC AND VECTOR LABORATORIES, INC., AS BORROWERS, MARAVAI TOPCO HOLDINGS, LLC, AS HOLDINGS,...Credit Agreement • October 29th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • New York
This CREDIT AGREEMENT is entered into as of October 19, 2020, among MARAVAI INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Parent Borrower”), CYGNUS TECHNOLOGIES, LLC, a Delaware limited liability company (“Cygnus”), TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“TriLink”), Vector Laboratories, Inc., a California corporation (“Vector”; and together with the Parent Borrower, Cygnus and TriLink, the “Borrowers” and each, a “Borrower”), MARAVAI TOPCO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), each L/C Issuer party hereto and MORGAN STANLEY SENIOR FUNDING, INC. (“MS”), as Administrative Agent and Collateral Agent.
TAX RECEIVABLE AGREEMENT BY AND AMONG MARAVAI LIFESCIENCES HOLDINGS, INC., CERTAIN OTHER PERSONS NAMED HEREIN, AND THE AGENT DATED AS OF NOVEMBER 19, 2020Tax Receivable Agreement • November 25th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
This TAX RECEIVABLE AGREEMENT (this “Agreement”), dated as of November 19, 2020 is hereby entered into by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Corporation”), Maravai Topco Holdings, LLC, a Delaware limited liability company (the “Company”), Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (“MLSH 1”), Maravai Life Sciences Holdings 2, LLC, a Delaware limited liability company (“MLSH 2”), and the Agent.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 9th, 2023 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and William “Trey” Martin, III (“Executive”). Capitalized terms used but not otherwise defined shall have the meanings set forth in Section 4.
MARAVAI TOPCO HOLDINGS, LLC SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of November 19, 2020Limited Liability Company Agreement • November 25th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT of Maravai Topco Holdings, LLC, a Delaware limited liability company (the “Company”), is entered into as of November 19, 2020, by and among the Company, Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Maravai Co.”), and Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (“Holdings”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in Article I.
EXCHANGE AGREEMENTExchange Agreement • November 25th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
SENIOR MANAGEMENT AGREEMENTSenior Management Agreement • October 29th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS SENIOR MANAGEMENT AGREEMENT (this “Agreement”) is made as of March 18, 2014, by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), Maravai Life Sciences, Inc., a Delaware corporation (“Employer”), and Carl W. Hull (“Executive”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 10 of this Agreement, or if not defined herein, the meanings in the LLC Agreement.
INVESTMENT AND DIRECTOR COMPENSATION AGREEMENTInvestment and Director Compensation Agreement • October 29th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTMENT AND DIRECTOR COMPENSATION AGREEMENT (this “Agreement”) is made as of January 1, 2017 by and between Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”) and Robert B. Hance (“Director”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in Section 8 of this Agreement, or if not defined herein, the meanings in the LLC Agreement.
DIRECTOR NOMINATION AGREEMENTDirector Nomination Agreement • November 25th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS DIRECTOR NOMINATION AGREEMENT (this “Agreement”) is made and entered into as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (“MLSH 1”), Maravai Life Sciences Holdings 2, LLC, a Delaware limited liability company (“MLSH 2”), GTCR Fund XI/C LP, a Delaware limited partnership, GTCR Fund XI/B LP, a Delaware limited partnership, GTCR Co-Invest XI LP, a Delaware limited partnership, GTCR Partners XI/A&C LP, a Delaware limited partnership, GTCR Partners XI/B LP, a Delaware limited partnership and GTCR Investment XI LLC, a Delaware limited liability company (collectively, “GTCR”). This Agreement shall be effective from the date hereof (the “Effective Date”).
THIRD AMENDMENT TO LEASE AGREEMENTLease Agreement • October 14th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • California
THIS LEASE AGREEMENT (this “Lease”) is made as of July , 2018 (“Effective Date”)’ by and between 10770 WATERIDGE INVESTORS LLC, a California limited liability company (“Landlord”), and TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“Tenant”).
FIRST LIEN CREDIT AGREEMENTFirst Lien Credit Agreement • October 14th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • New York
This FIRST LIEN CREDIT AGREEMENT is entered into as of August 2, 2018, among MARAVAI INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Parent Borrower”), CYGNUS TECHNOLOGIES, LLC, a Delaware limited liability company (“Cygnus”), TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“TriLink”), Vector Laboratories, Inc., a California corporation (“Vector”; and together with the Parent Borrower, Cygnus and TriLink, the “Borrowers” and each, a “Borrower”), MARAVAI TOPCO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), each L/C Issuer party hereto and JPMORGAN CHASE BANK, N.A. (“JPMCB”), as Administrative Agent and Collateral Agent.
AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 29th, 2024 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”), entered into on July 27, 2023 (the “Effective Date”), is by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W. Hull (“Executive”).
FORM OF SENIOR MANAGEMENT AGREEMENT (CAPITAL UNITS AND INCENTIVE UNITS)Senior Management Agreement • February 28th, 2023 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS SENIOR MANAGEMENT AGREEMENT (this “Agreement”) is made as of [●], by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [Maravai Life Sciences, Inc.], a Delaware corporation (“Employer”), and [●] (“Executive”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 10 of this Agreement, or if not defined herein, the meanings in the LLC Agreement.
FIFTH AMENDMENT TO DEED OF LEASEDeed of Lease • October 29th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • New York
THIS FIFTH AMENDMENT TO DEED OF LEASE (this “Amendment”) is made as of this 23rd day of September, 2019, (the “Effective Date”), by and between QUANTICO BUILDINGS, LLC, a Delaware limited liability company (“Landlord”), and GLEN RESEARCH CORPORATION, a Virginia corporation (“Tenant”).
LEASE AGREEMENT BETWEEN 10240 FLANDERS INVESTORS LLC, a Delaware limited liability company (LANDLORD) AND TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (TENANT) August 6, 2021 10240-10247 FLANDERS COURT SAN DIEGO, CALIFORNIALease Agreement • February 29th, 2024 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of January 19, 2022 (this “Amendment”), amends that certain Credit Agreement, dated as of October 19, 2020 (as amended, restated, amended and restated,...Credit Agreement • January 20th, 2022 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • New York
SECOND AMENDMENT TO LEASE AGREEMENTLease Agreement • February 29th, 2024 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LEASE AGREEMENT (“Amendment”) is entered into as of October 1, 2022 (“Effective Date”), by and between 10240 FLANDERS INVESTORS LLC, a Delaware limited liability company (“Landlord”), and TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“Tenant”), with reference to the facts set forth in the Recitals below.
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • September 3rd, 2021 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this ”Amendment”), is made as of September 2, 2021, by and among Maravai Life Sciences, Inc., a Delaware corporation (“Seller”), Voyager Group Holdings, Inc., a Delaware corporation (“Parent”), VYGR Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Maravai LifeSciences Holdings”), and Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Maravai Intermediate Holdings” and together with Maravai Holdings, each, a “Maravai Guarantor” and collectively, the “Maravai Guarantors”).
SECOND LIEN CREDIT AGREEMENTLien Credit Agreement • October 14th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • New York
This SECOND LIEN CREDIT AGREEMENT is entered into as of August 2, 2018, among MARAVAI INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Parent Borrower”), CYGNUS TECHNOLOGIES, LLC, a Delaware limited liability company (“Cygnus”), TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“TriLink”), Vector Laboratories, Inc., a California corporation (“Vector”; and together with the Parent Borrower, Cygnus and TriLink, the “Borrowers” and each, a “Borrower”), MARAVAI TOPCO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), and ANTARES CAPITAL LP (“Antares”), as Administrative Agent and Collateral Agent.
FORM OF AMENDMENT TO SENIOR MANAGEMENT AGREEMENTSenior Management Agreement • February 28th, 2023 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT TO THE SENIOR MANAGEMENT AGREEMENT (this “Amendment”), effective as of [●], is made by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [●]1 (“Employer”), [●] (“Executive”), GTCR Fund XI/B LP, a Delaware limited partnership (“Fund XI/B”), GTCR/Maravai Splitter LP, a Delaware limited partnership (“Splitter”), and GTCR Co-Invest XI LP, a Delaware limited partnership (“GTCR Co-Invest” and together with Fund XI/B and Splitter, the “Majority Holders”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement (as defined below).
LEASE Basic Lease InformationBasic Lease Information • October 29th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
THIS LEASE, made as of the date specified in the Basic Lease Information, by and between the landlord specified in the Basic Lease Information (“Landlord”), and the tenant specified in the Basic Lease Information (“Tenant”).
AMENDMENT NO. 1 TO PERFORMANCE STOCK UNIT GRANT NOTICEPerformance Stock Unit Grant Notice • August 8th, 2023 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO PERFORMANCE STOCK UNIT GRANT NOTICE (this “Amendment”) is entered into effective as of July 6, 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and William E. Martin, III (“Participant”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in that certain Performance Stock Unit Grant Notice and Performance Stock Unit Agreement (the “Agreement”), by and between the Company and Participant, dated as of October 17, 2022 (the “Grant Date”).
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • February 29th, 2024 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is dated as of August 11, 2021 and is entered into by and among MARAVAI INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Parent Borrower”), and MORGAN STANLEY SENIOR FUNDING, INC. (“MS”), as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), and amends that certain Credit Agreement, dated as of October 19, 2020, by and among Parent Borrower, CYGNUS TECHNOLOGIES, LLC, a Delaware limited liability company (“Cygnus”), TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“TriLink”), Vector Laboratories, Inc., a California corporation (“Vector”; and together with the Parent Borrower, Cygnus and TriLink, the “Borrowers” and each, a “Borrower”), MARAVAI TOPCO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), each lender from time to time party thereto (collectively, the “Lenders”), each L/C Issuer party hereto, the Administrative Agent and MS, as Colla
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • October 3rd, 2022 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), entered into on September 29, 2022 is by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W. Hull (“Executive”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SUPPLY AGREEMENTSupply Agreement • November 9th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
This SUPPLY AGREEMENT (this “Agreement”), is made as of October 9, 2020 (the “Effective Date”), by and among Pfizer Inc., a Delaware corporation, having an address of 235 East 42nd Street, New York, New York 10017 (“Pfizer”), BioNTech SE, a company organized and existing under the laws of Germany, having an address of An der Goldgrube 12, 55131 Mainz, Germany (“BioNTech”) (each of Pfizer and BioNTech, a “Customer Party,” and collectively, “Customer”) and TriLink BioTechnologies, LLC, a Delaware limited liability company, having an address of 10770 Wateridge Circle, Suite 200, San Diego, CA 92121 (“Supplier”). Customer and Supplier may be referred to herein individually as a “Party” or collectively as the “Parties”.
AMENDMENT NO. 1 TO RESTRICTED STOCK UNIT GRANT NOTICERestricted Stock Unit Grant Notice • August 8th, 2023 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO RESTRICTED STOCK UNIT GRANT NOTICE (this “Amendment”) is entered into effective as of [_______], 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and [_____________] (“Participant”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in that certain Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (the “Agreement”), by and between the Company and Participant, dated as of [________] (the “Grant Date”).
DISTRIBUTION AGREEMENTDistribution Agreement • October 14th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • California
This agreement (“Agreement”) is made and entered into on January 14, 2019 (“Effective Date”) between Cygnus Technologies, with a place of business at 4332 Southport Supply Rd., SE, Southport, NC 28461 USA (referred to herein as “Cygnus”), and BEIJING XMJ SCIENTIFIC CO., LTD, with a place of business at Rm 6C, Block C, Golden Resources Business Center, No.2 Landianchang East Rd, Haidian District, Beijing, China (referred to herein as “Distributor”), each a “Party” and together, the “Parties”.
AGREEMENT AND PLAN OF MERGER by and among MARAVAI LIFE SCIENCES, INC.,Agreement and Plan of Merger • August 10th, 2021 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
This AGREEMENT AND PLAN OF MERGER (“Agreement”) is made as of August 5, 2021, by and among Maravai Life Sciences, Inc., a Delaware corporation (“Seller”), Voyager Group Holdings, Inc., a Delaware corporation (“Parent”), VYGR Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Maravai LifeSciences Holdings”), and Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Maravai Intermediate Holdings” and together with Maravai Holdings, each, a “Maravai Guarantor” and collectively, the “Maravai Guarantors”).
SECOND AMENDED & RESTATED ADVISORY AGREEMENTAdvisory Agreement • October 14th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED & RESTATED ADVISORY AGREEMENT (this “Agreement”) is made as of September 15, 2016, by and among GTCR Management XI LP, a Delaware limited partnership (“GTCR”), Vector Laboratories, Inc., a California corporation (“Vector”), and TriLink BioTechnologies, LLC, a Delaware limited liability company (“TriLink” and, together with Vector, each an “Opco” and collectively “Opcos”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Limited Liability Company Agreement of the Company (as defined below), dated as of April 5, 2016, among the parties from time to time party thereto (as amended or modified from time to time, the “LLC Agreement”).
●] Shares MARAVAI LIFESCIENCES HOLDINGS, INC. CLASS A COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENTUnderwriting Agreement • April 6th, 2021 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • November 25th, 2020 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W. Hull (“Executive”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 4.
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 9th, 2024 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations • California
THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of February 25, 2024 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), TriLink Biotechnologies, LLC, a Delaware limited liability company (“Employer”), and Andrew Burch (“Executive”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 4.
SENIOR MANAGEMENT AGREEMENTMaravai Lifesciences Holdings, Inc. • October 14th, 2020 • Pharmaceutical preparations • Delaware
THIS SENIOR MANAGEMENT AGREEMENT (this “Agreement”) is made as of December 27 , 2017, by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), TriLink Biotechnologies, LLC, a Delaware limited liability company (“Employer”), and Brian Neel (“Executive”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 8 of this Agreement, or if not defined herein, the meanings in the LLC Agreement.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. FIRST AMENDMENT TO...Supply Agreement • September 3rd, 2021 • Maravai Lifesciences Holdings, Inc. • Pharmaceutical preparations
This First Amendment (“First Amendment”) is made as of August 30, 2021 (the “Execution Date”) and effective as of June 6, 2021 (the “Effective Date”) by and between TriLink BioTechnologies, LLC (“TriLink”), Pfizer Inc. (“Pfizer”), and BioNTech SE (“BioNTech”), each individually referred to herein as a “Party” and collectively as the “Parties”.
